# Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition

> **NCT05721326** · NA · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 1330 (actual)

## Conditions studied

- Genetic Predisposition to Disease
- Breast Cancer Female
- Ovarian Cancer
- Hereditary Breast and Ovarian Cancer
- Hereditary Cancer Syndrome
- Hereditary Diseases
- Gene Mutation-Related Cancer

## Interventions

- **OTHER:** Sequential EHR Communications

## Key facts

- **NCT ID:** NCT05721326
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 1330 (ACTUAL)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05721326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05721326, "Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05721326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*